Sort   by:  
 Page size 
UnknownEffect of Low-Fat Diet in Obese Mice Lacking Toll-like Receptors.
Not available
S-EPMC6213519 | biostudies-literature
UnknownWeight-reduction through a low-fat diet causes differential expression of circulating microRNAs in obese C57BL/6 mice.
Not available
S-EPMC4571067 | biostudies-literature
UnknownIdentification of Circulating miRNAs in a Mouse Model of Nerve Allograft Transplantation under FK506 Immunosuppression by Illumina Small RNA Deep Sequencing.
Not available
S-EPMC4578739 | biostudies-literature
UnknownExploring the Multifunctional Roles of Odontoglossum Ringspot Virus P126 in Facilitating Cymbidium Mosaic Virus Cell-to-Cell Movement during Mixed Infection.
Not available
S-EPMC8402721 | biostudies-literature
UnknownElectric control of a canted-antiferromagnetic Chern insulator.
Not available
S-EPMC8964814 | biostudies-literature
ProteomicsThe changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylati...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054332 | Pride
Human Lc-msms Hnscc Cetuximab resistance Acetylation 
ProteomicsThe changes in HNSCC cell lines (e.g., OECM1) when treated with Cetuximab (500 ug/ml) at different passages. We used LC-MS/MS to identify the main target pathway. These findings could significantly enhance our evidence.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We collected serial passages of cetuximab resistance HNSCC cell lines to perform LC-MS/MS. We identified the IFN p...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054113 | Pride
Human Lc-msms Hnscc Cetuximab 
ProteomicsThe changes in cetuximab resistant HNSCC cell lines (e.g., OECM1-cetuximabR and CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main phosphorylation sites in resistance cell lines.
Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the phosphorylation sites in wild-type and resistant cells. We proposed that the phosp...
ORGANISM(S): Homo sapiens (Human) 
2025-12-29 | PXD054186 | Pride
Human Lc-msms Hnscc Cetuximab resistance Phosphorylation 
UnknownGlutamylation of centrosomes ensures their function by recruiting microtubule nucleation factors.
Not available
S-EPMC12084555 | biostudies-literature
UnknownTherapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy.
Not available
S-EPMC12711663 | biostudies-literature
Sort   by:  
 Page size